OpenAI has launched a new artificial intelligence (AI) model, known as GPT-Rosalind Franklin, with the aim of accelerating research in biology, drug discovery and medicine. It is named after Rosalind Franklin, the British scientist who played a key role in discovering the structure of DNA.
The model is designed to handle complex scientific work involving published research, biological data, laboratory tools, and experiments. It is most effective in tasks involving reasoning about molecules, proteins, genes and disease biology.
GPT-Rosalind is designed to operate in multi-step scientific workflows, including literature reviews, genetic sequence analysis, experiment planning, and research data processing.
The San Francisco-based company says its new AI model can surface connections that researchers might otherwise miss and help scientists reach better conclusions more quickly.
According to OpenAI, progress in the life sciences is held back not only by the difficulty of the science, but also by the complexity of the research process itself. He believes advanced AI can help researchers navigate these workflows more efficiently.
“We believe that advanced AI systems can help researchers explore more possibilities and form better hypotheses more quickly,” the company said in its statement.
He describes GPT-Rosalind as the start of a long-term commitment to develop AI capable of driving scientific discovery in areas important to society.
OpenAI already works with several major players in the biotechnology and pharmaceutical industries, including Amgen, Moderna, the Allen Institute and Thermo Fisher Scientific.
Moderna CEO Stéphane Bancel said the model already showed promise, adding that it could bring together complex data and transform that information into practical experimental workflows, with the potential to accelerate research and development.
GPT-Rosalind is part of a broader OpenAI initiative in health and medical research. The company develops new AI models and forms partnerships with global pharmaceutical companies.
OpenAI has announced a partnership with Danish pharmaceutical giant Novo Nordisk in an effort to help the company bring new and better treatments to patients more quickly.
Sam Altman, CEO of OpenAI, said: “AI is reshaping industries and, in life sciences, it can help people live better and longer. »
